Literature DB >> 12448868

An epidemiologic study of hepatocellular carcinoma in Canada.

Susie elSaadany1, Martin Tepper, Yang Mao, Robert Semenciw, Antonio Giulivi.   

Abstract

BACKGROUND AND METHODS: To provide information on poorly described Canadian hepatocellular cancer epidemiology, we analyzed incident cases abstracted from the Canadian Cancer Registration Database (1969-1997) and Canadian annual death data (1969-1998). Age, sex, geographic distribution, and secular trends were described. Projection models were developed for the next decade.
RESULTS: Results indicated much higher incidence and mortality rates in males than females, with substantial increases for both with age. Age-standardized incidence rates increased an average of 3.4% per year in males, 1.2% per year in females (1969-1997). Age-standardized mortality rates increased an average of 1.48% in males, but decreased an average of 0.46% per year in females (1969-1998). Join-point analysis of the linear trends in the age-standardized incidence and mortality rates suggested that a new trend started to emerge about 1991. The fitted non-linear multiplicative model predicted the occurrence of 1,565 new cases and 802 deaths in the year 2010. HCC incidence was the highest in British Colombia, followed by Quebec, and the lowest in the Atlantic region.
CONCLUSIONS: Incidence rates of hepatocellular carcinoma have increased substantially, consistent with the reported increase in the prevalence of Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) infections in recent decades.

Entities:  

Mesh:

Year:  2002        PMID: 12448868      PMCID: PMC6979680     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  16 in total

1.  Do drinking surveys predict changes in population-based alcohol problem indicators?

Authors:  R G Smart; H M Suurvali; R E Mann
Journal:  Alcohol Alcohol       Date:  2000 May-Jun       Impact factor: 2.826

Review 2.  Current status of hepatitis C in Canada.

Authors:  S Zou; M Tepper; A Giulivi
Journal:  Can J Public Health       Date:  2000 Jul-Aug

3.  Treatment, Alcoholics Anonymous and alcohol controls during the decrease in alcohol problems in Alberta: 1975-1993.

Authors:  R G Smart; R E Mann
Journal:  Alcohol Alcohol       Date:  1998 May-Jun       Impact factor: 2.826

Review 4.  Screening for hepatocellular carcinoma.

Authors:  J Collier; M Sherman
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

5.  Trends in primary liver cancer.

Authors:  S Deuffic; T Poynard; L Buffat; A J Valleron
Journal:  Lancet       Date:  1998-01-17       Impact factor: 79.321

6.  Prediction of hepatitis C burden in Canada.

Authors:  S Zou; M Tepper; S El Saadany
Journal:  Can J Gastroenterol       Date:  2000 Jul-Aug       Impact factor: 3.522

7.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

8.  Trends of liver cirrhosis mortality in Europe, 1970-1989: age-period-cohort analysis and changing alcohol consumption.

Authors:  G Corrao; P Ferrari; A Zambon; P Torchio; S Aricò; A Decarli
Journal:  Int J Epidemiol       Date:  1997-02       Impact factor: 7.196

9.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

10.  A nested case-control study on association between hepatitis C virus antibodies and primary liver cancer in a cohort of 9,775 men in Taiwan.

Authors:  C C Chang; M W Yu; C F Lu; C S Yang; C J Chen
Journal:  J Med Virol       Date:  1994-07       Impact factor: 2.327

View more
  10 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

2.  VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication.

Authors:  Jun Yi; Wei-Dong Gong; Ling Wang; Rui Ling; Jiang-Hao Chen; Jun Yun
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

3.  Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Kathy Han; George N Tzimas; Jeffrey S Barkun; Peter Metrakos; Jean L Tchervenkov; Nir Hilzenrat; Phil Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

4.  Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.

Authors:  Jian Ming Fan; Qiao Zhang; Jun Xu; Sha Zhu; Tao Ke; De Fu Gao; Yu Bao Xu
Journal:  Mol Biol Rep       Date:  2007-12-05       Impact factor: 2.316

5.  Anti-HBV activity of TRL mediated by recombinant adenovirus.

Authors:  Wei-Dong Gong; Ya Zhao; Jun Yi; Jin Ding; Jun Liu; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

Review 6.  An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm.

Authors:  Kelly W Burak; Norman M Kneteman
Journal:  Can J Gastroenterol       Date:  2010-11       Impact factor: 3.522

7.  Inhibition of HBV targeted ribonuclease enhanced by introduction of linker.

Authors:  Wei-Dong Gong; Jun Liu; Jin Ding; Ya Zhao; Ying-Hui Li; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

8.  The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004.

Authors:  Robert P Myers; MingFu Liu; Abdel Aziz Shaheen
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

9.  Hepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C.

Authors:  Clement Ibi Mboto; Angela Davies-Russell; Mark Fielder; Andrew Paul Jewell
Journal:  Int Semin Surg Oncol       Date:  2005-10-04

10.  Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.

Authors:  Jianwai Ren; George G Chen; Yi Liu; Xianwei Su; Baoguang Hu; Billy C S Leung; Y Wang; Rocky L K Ho; Shengli Yang; Gang Lu; C G Lee; Paul B S Lai
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.